Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The history of the oxazaphosphorine cytostatics.
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Phase II Cladribine Add-on to Interferon-beta (IFN-b) Therapy in MS Subjecs With Active Disease (ONWARD)
Vaccines and the Risk of Multiple Sclerosis and Other Central Nervous System Demyelinating Diseases.
Glatiramer acetate does not protect from acute ischemic stroke in mice.
Preventive effect of vitamin D3 supplementation on conversion of optic neuritis to clinically definite multiple sclerosis: a double blind, randomized, placebo-controlled pilot clinical trial.
Treatment with 4-aminopyridine improves upper limb tremor of a patient with multiple sclerosis: a video case report.
Dalfampridine sustained-release for symptomatic improvement of walking speed in patients with multiple sclerosis.
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer's disease.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.
Safety issue puts daclizumab in doubt for MS
Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-α
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Frequency of Comorbidities and Their Association with Clinical Disability and Relapse in Multiple Sclerosis.
Laquinimod for multiple sclerosis.
Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis.
Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.
The NF-κB regulator MALT1 determines the encephalitogenic potential of Th17 cells.
Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis.
Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain.
Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.
BRIEF-AB Science says DSMB recommends continuation of phase 3 masitinib study
Saccadic intrusions: review and update.

Pages